Teva Czech Industries Deploys Ness Technologies Oracle E-Business Suite
The project, which is worth $2m, is expected to be operational on January 1, 2011. Ness Technologies will support the project through the end of April 2011. The
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.